Primary Endpoint In Phase 2 Study Of Ifenprodil For Idiopathic Pulmonary Fibrosis, Chronic Cough
18/07/2022 14:10
July 18 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS HITS CO-PRIMARY ENDPOINT IN ITS
PHASE 2
STUDY OF IFENPRODIL FOR IDIOPATHIC PULMONARY FIBROSIS AND
CHRONIC COUGH
* ALGERNON PHARMACEUTICALS HITS CO-PRIMARY ENDPOINT IN ITS
PHASE 2
STUDY OF IFENPRODIL FOR IDIOPATHIC PULMONARY FIBROSIS AND
CHRONIC COUGH
Source text for Eikon: ID:nGNX4js0WD
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement